Lamotrigine chewable dispersible tablet

Drug Profile

Lamotrigine chewable dispersible tablet

Alternative Names: Lamotrigine CD; Lamictal CDT; Lamotrigine CD tablet; Lamotrigine chewable tablet; Lamotrigine dispersible tablet

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bipolar disorders; Epilepsy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 GlaxoSmithKline completes a phase III trial in Bipolar disorders in China (NCT01602510)
  • 01 Nov 2015 GlaxoSmithKline completes a phase I trial In volunteers in China (PO) (NCT02513654)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top